ProfileGDS5678 / 1451798_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 74% 77% 74% 73% 75% 80% 74% 77% 76% 73% 74% 73% 71% 69% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.7883374
GSM967853U87-EV human glioblastoma xenograft - Control 25.2435277
GSM967854U87-EV human glioblastoma xenograft - Control 34.8300674
GSM967855U87-EV human glioblastoma xenograft - Control 44.7569173
GSM967856U87-EV human glioblastoma xenograft - Control 55.0496275
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.4436680
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.7785974
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.1968877
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.0663676
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.7492173
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.7655274
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.7688973
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.4769771
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.2860169